Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Related MYL
Top 4 Small-Cap Stocks In The Drugs-Generic Industry With The Lowest PEG Ratio
Mylan Launches First Generic Version Of Orapred ODT
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)
Related SLXP
Credit Suisse Raises Salix Pharmaceuticals Price Target
#PreMarket Movers From December 16, 2014
Making Money With Charles Payne: 10/17/14 (Fox Business)

Below are the top drugs-generic stocks on the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Mylan (NASDAQ: MYL) is $6.39 billion. Mylan's ROA for the same period is 5.89%.

The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd (NASDAQ: SLXP) is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Hi Tech Pharmacal Co (NASDAQ: HITK) is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%.

The trailing-twelve-month revenue at Akorn (NASDAQ: AKRX) is $163.19 million. Akorn's operating margin for the same period is 26.68%.

Posted-In: Drugs-Generic Industry Highest Revenue NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

Around the Web, We're Loving...

Get Benzinga's Newsletters